| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2025/03/06 | 19 : 45 | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/05 | 06 : 43 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/05 | 06 : 34 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/05 | 06 : 28 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/05 | 06 : 26 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/05 | 06 : 24 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/05 | 06 : 21 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/05 | 06 : 01 | GlobeNewswire Inc. | Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/03 | 19 : 45 | PR Newswire (US) | NTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/03/01 | 06 : 02 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/28 | 06 : 03 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/27 | 21 : 45 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/27 | 21 : 30 | GlobeNewswire Inc. | Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/27 | 19 : 45 | PR Newswire (US) | The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/24 | 19 : 45 | PR Newswire (US) | Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NTLA | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/22 | 06 : 06 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/20 | 21 : 30 | GlobeNewswire Inc. | Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/20 | 19 : 45 | PR Newswire (US) | The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/13 | 19 : 45 | PR Newswire (US) | The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/05 | 06 : 01 | GlobeNewswire Inc. | Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/02/01 | 06 : 17 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/24 | 07 : 41 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/22 | 21 : 30 | GlobeNewswire Inc. | Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/10 | 21 : 30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/10 | 06 : 00 | GlobeNewswire Inc. | Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/08 | 07 : 23 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/08 | 07 : 22 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/08 | 07 : 20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/08 | 07 : 20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
| 2025/01/08 | 07 : 16 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NTLA | Intellia Therapeutics Inc |
